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Purpose: Mutations in the transforming growth factor β-induced protein (TGFBIp) are associated 
with TGFBI-linked corneal dystrophies, which manifests as protein deposits in the cornea. A total 
of 70 different disease-causing mutations have been reported so far including the common R124H 
substitution, which is associated with granular corneal dystrophy type 2 (GCD2). The disease 
mechanism of GCD2 is not known and the current treatments, such as corneal transplantation, only 
offer temporary relief due to the reoccurrence of deposits. In this study, we compared the corneal 
protein profiles of the three genotypes (wild-type (WT), heterozygotes, and homozygotes) of a 
GCD2 mouse model using label-free quantitative LC-MS/MS.  
Results: The mice do not display any corneal protein deposits and the global protein expression 
between the three genotypes is highly similar. However, the expression of mutated TGFBIp is 41% 
of that of the WT protein.  
Conclusions and Clinical Relevance: It is proposed that the lowered expression level of mutant 
TGFBI protein relative to WT protein is the direct cause of the missing development of corneal 
deposits in the mouse. The overall protein profiles of the corneas were not impacted by the reduced 
amount of TGFBIp. Altogether, this supports a partial reduction in mutated TGFBIp as a potential 
treatment strategy for GCD2. 
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Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix (ECM) protein 
that is highly abundant in the human cornea.[1] Mutations in TGFBIp are associated with corneal 
dystrophies where protein accumulation in the cornea leads to loss of normal vision. Granular 
corneal dystrophy type 2 (GCD2), also called Avellino corneal dystrophy, has a mixed phenotype 
of both amorphous and amyloid deposits, with amyloid deposits appearing in the more advanced 
stage of the disease. To date, 70 different mutations in TGFBIp have been reported in relation to 
corneal dystrophies, one of which is the common R124H mutation, which causes GCD2.[2] Patients 
that are homozygous for the R124H TGFBIp mutation usually develop corneal opacities in the first 
decade of life and have a more severe phenotype than heterozygous GCD2 patients, who experience 
onset of the disease later in life. The current treatments of TGFBI-linked corneal dystrophies include 
corneal transplantation and corneal ablation of the affected area. Unfortunately, these treatments 
only offer temporary relief and the protein deposits will reoccur. 
 The mechanisms responsible for the TGFBIp aggregation in the cornea of GCD2 patients are 
unknown. Animal models are useful in elucidating the pathogenesis and treatment strategies of 
diseases and one mouse model showing a TGFBI-related corneal dystrophy phenotype has so far 
been developed.[3] Human TGFBI cDNA with the R124H mutation was inserted into the first exon 
of the mouse TGFBI DNA generating the transgenic TGFBIR124H mouse model. In the original 
paper, the mice developed corneal opacities with total incidence rates of 0.0% in wild-type (WT), 
19.4% in heterozygotes, and 45.0% in homozygotes.[3] The expression of TGFBIR124H was 
confirmed by RT-PCR and protein staining confirmed the presence of amorphous and amyloid 
deposits in the anterior stroma. The mouse model reflects the human cases of GCD2 by having a 
higher incidence of granular opacities in homozygotes than in heterozygotes and a higher incidence 




 We have previously performed proteomic profiling of normal and plaque corneal tissue from 
patients with GCD2 caused by the R124H mutation.[4, 5] These studies showed that the protein 
composition and relative protein abundance in the deposits differed from the control samples. 
Accumulation of intact or nearly full-length TGFBIp in the protein deposits and a slight difference 
in proteolytic processing were also observed.  
 In this study we analysed the proteome of R124H transgenic mouse corneas in an attempt to 
understand the disease mechanisms leading to the GCD2 phenotype. We compared the corneal 
proteome of three WT, heterozygous, and homozygous mice (Supporting Information 1), and 
analysed the corneal protein composition and relative amount of TGFBIp. All the mice studied had 
not developed corneal deposits. 
 Detailed method descriptions are found in Supporting Information 2. All work in mice 
described within was conducted under the Animals (Scientific Procedures) Act 1986, Section 5, 
through a project license granted to Professor Tara Moore by the Department of Health which 
specified a programme of work and authorized that programme, of specified regulated procedures 
to animals of specified descriptions at a specified place or specified places. The eyes of the mice 
used for proteome analysis were examined for corneal deposits using a surgical microscope. No 
corneal deposits were observed in any of the corneas, though mice within this age (43-57 weeks) 
were expected to have the following incidence of corneal opacity: 0.0 % in WT, 12.5 % in 
heterozygotes, and 42.9 % in homozygotes.[3] Additional, heterozygous and homozygous mice 
(n=10 per group) at the age from three months to two years were also examined and did not show 
any deposits. The left corneas were subjected to CNBr chemical cleavage followed by enzymatic 
trypsin digestion. The recovered peptides were analysed by LC-MS/MS using a Q Exactive Plus 
mass spectrometer (ThermoFisher Scientific). The MS data were searched and quantified using 
MaxQuant (version 1.6.5.0) performing label-free quantification (LFQ) based on minimum of two 
peptides from each protein and searched against the Uniprot mouse reference proteome (version 
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23_09_2019; 21960 sequences) supplemented with the human TGFBIp sequence (Uniprot 
accession number: Q15582) modified with the R124H substitution. The data were processed in 
Perseus (version 1.5.3.2) and protein identification was based on a 1 % FDR threshold. Proteins 
were only included for quantification if they were quantified in all three biological replicates of each 
genotype group. A total of 525 proteins were quantified in WT corneas, 544 in heterozygotes, and 
508 in homozygotes (Table 1, Supporting Information 3 and 4) herof a total of 444 quantified in all 
three genotypes (Fig. 1A, Supporting Information 5). 
 The 25 most abundant proteins in each genotype were highly similar and did not reveal any 
major changes (Table 1). No significant regulated proteins apart from TGFBIp were found by 
student’s t-test between WT and heterozygous/homozygous corneas (Supplemental Information 6). 
ECM proteins like collagens, keratocan, serum albumin, alpha-2-macroglobulin, lumican, and 
decorin were highly represented among the most abundant proteins (Table 1). Aldehyde 
dehydrogenase was also highly abundant and is known to constitute up to 40 % of the soluble protein 
in the mammalian corneal epithelium.[6] Transketolase is also known to be a major protein in the 
corneal epithelial cells and comprise 10 % of the soluble proteins in the adult mouse cornea.[7] 
 We confirmed expression of R124H TGFBIp in heterozygotes and homozygotes by detection 
of a peptide containing the R124H amino acid substitution (Fig. 1B). TGFBIp was found to be 
differentially expressed by ANOVA analysis, which was expected since the three genotypes have 
different combinations of the human and mouse protein. The razor peptides (peptide sequences not 
unique to one protein) between human R124H TGFBIp and mouse WT TGFBIp were assigned to 
the mouse accession number (P82198). In order to obtain the total amount of TGFBIp in the 
heterozygotes and homozygotes the LFQ intensity of human and mouse TGFBIp were added 
together. This resulted in TGFBIp being the 24th and 22th most abundant protein in heterozygotes 
and homozygotes respectively, both with a molar percentage of 0.7 ± 0.1 (Table 1). In WT corneas 
TGFBIp ranked as the 16th most abundant protein with a molar percentage of 1.0 ± 0.0. The 
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difference in molar percentage led us to examine the amount of TGFBIp expression in the different 
genotypes further. Relative quantification based on the intensities of the shared razor peptides 
showed that the protein level of mutated TGFBIp was 41 % of that of the endogenous WT protein 
(Fig. 1C). The lower intensity of TGFBIp in homozygote compared to WT were also confirmed by 
2DE on the right corneas (Supplemental Information 7). The disease mechanism of GCD has been 
linked to change in solubility and/or stability of the mutated protein.[8]  This may cause TGFBIp to 
aggregate due to the high TGFBIp concentration in the cornea. The lower expression of the mutated 
protein observed in this study could, therefore, explain the lack of deposits in the TGFBIR124H 
corneas. In humans, TGFBIp is the second most abundant protein in the human cornea making up 
1% of the epithelium, 17.6% of the stroma, and 36.8% of the endothelium and Descemets	
membrane.[1] We previously found the amount of TGFBIp in mouse cornea to be 10-fold lower 
than in humans, which is supported by the lower molar percentage in our results compared to the 
human corneal proteome.[9] 
 The disease mechanism of TGFBI-linked corneal dystrophies has in several studies been 
linked to altered stability and aberrant proteolytic processing of the disease-causing TGFBIp 
mutants.[4,8,10] We performed 2DE of the proteins in the right cornea of the different genotypes and 
subsequently immunoblotted against TGFBIp. The immunoblots showed a lower intensity of 
TGFBIp in the homozygote compared to WT, supporting the proteomics data. A high molecular 
weight cluster (Figure 2, HMw) together with a low molecular weight cluster (Figure 2, LMw 1) 
were observed in all genotypes. The heterozygote and the homozygote showed another low 
molecular weight cluster (Figure 2, LMw 2) indicating altered proteolytic processing in accordance 
with previous studies but could also be caused by a difference in the primary sequence of human 
and mouse TGFBIp.[4,5] Furthermore, the characteristic “zigzag” degradation pattern seen for human 
corneal TGFBIp appeared less pronounced in mice, and TGFBIp isoforms displayed a shift toward 
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a lower pI in mice than in human cornea.[11] This may be due to differential processing of TGFBIp 
between the two species, which is supported by the TGFBIR124C mouse model recently 
developed.[12]  
In this study, we found the mutant expression in the TGFBIR124H mouse model to be 41 % of the 
WT protein. Based on previous reports we expected some of these mice to show deposits [3] and we 
suggest that the lack thereof is due to the low mutant TGFBIp amount. Quantitation of mutated 
TGFBIp was not addressed in the original paper characterizing the TGFBIR124H mice that developed 
deposits.[3] We assume equal expression level of mutant and WT TGFBIp in early generations of 
TGFBIR124H mice and suggest that several generations of breeding could have induced a lower 
expression due to genetic imprinting. Examination of methylation of the transgene promotor and 
flanking regions confirmed that they were differently methylated than the WT. Wheter the 
differential methylation affects transcription is unknown. Furthermore, the knock-in construct does 
not contain introns, which can be a source of reduced transgene expression. The slow disease 
progression and mild severity originally reported for this mouse model compared to human GCD2 
cases most likely reflects the generally lower TGFBIp protein level in mice compared to human 
cornea. Therefore, it is crucial for the generation of future TGFBI-linked corneal dystrophy mouse 
models to increase TGFBIp expression level to obtain a reliable phenotype development of corneal 
dystrophies within the life span of the mouse.  
 This study shows reduced amount of mutant protein and absence of phenotype, suggesting 
reduction of mutated TGFBIp as a novel treatment strategy in humans. Some studies have addressed 
this approach by RNA interference in cell culture and hold great potential for further testing.[10] 
Another therapeutic approach to reduce the amount of TGFBIp is CRISPR/Cas9 gene editing. This 
method can be used for mutant allele specific gene editing in heterozygotes reducing the amount of 
mutant TGFBIp while allowing the WT TGFBIp to be unaffected. This approach holds great 
promise for a therapeutic approach to a number of the TGFBI-linked corneal dystrophies and indeed 
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autosomal dominant disorders in general.[11] In the case of homozygotes it is necessary to reduce 
the expression of both mutant alleles. This study show that the protein profiles of the homozygotes, 
which had 41% reduction in TGFBIp amount compared to WT, did not change significantly. 
Furthermore, our previous studies showed only minor changes in the corneal structure of a TGFBI 
knock-out mouse model [9], altogether supporting corneal TGFBIp reduction as a mean to treat 
TGFBI-linked corneal dystrophies, without major disturbance of corneal homeostasis. 
 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE partner repository with the dataset identifier PXD012902 
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Figure 1. Venn diagram of expressed proteins and TGFBIp expression in the three genotypes. A) 
Venn diagram of the number of proteins quantified in WT, heterozygous (Het), and homozygous 
(Hom) TGFBIR124H mouse corneas. Full list of sorted accession numbers can be found in Supporting 
Information 5. B) Relative quantification of the human peptide containing the R124H mutation. C) 
Quantification of relative TGFBIp amount in the three genotypes based on intensity of razor 
peptides between the mouse and human sequence (n = 3 per genotype). The t-test p-values are 
indicated. 
 
Figure	 2.	 2DE immunoblots of TGFBIp in WT, heterozygous (Het), and homozygous (Hom) 
TGFBIR124H mouse corneas. The TGFBIp amount in the homozygote is lower than the WT and 
heterozygote and no accumulation of full-length (FL) protein in the homozygote was observed. A 
high and low molecular weight (HMw, LMw 1) cluster of proteolytic processed TGFBIp were 
present in all samples. Further degradation represented by another LMW cluster (LMw 2) was seen 








Table 1. Molar percentage of the 20 most abundant proteins in WT, Heterozygous, and Homozygous TGFBIR124H mice corneas 
WT Heterozygote Homozygote 
No.   Accession Protein name    Molar % No.  Accession Protein name    Molar% No.  Accession Protein name    Molar% 
1 P11087 Collagen alpha-1 
(I) chain 
17.9 ± 0.3 1 P11087 Collagen alpha-1 
(I) chain 
18.3 ± 2.5 1 P11087 Collagen alpha-1 
(I) chain 
19.7± 0.1 
2 Q01149 Collagen alpha-2 
(I) chain 
14.3 ± 0.3 2 Q01149 Collagen alpha-2 
(I) chain 
13.8 ± 2.1 2 Q01149 Collagen alpha-2 
(I) chain 
15.6 ± 0.4 
3 E9PWQ3 Collagen alpha-3 
(VI) chain 
9.7 ± 0.4 3 E9PWQ3 Collagen alpha-3 
(VI) chain 
8.8 ± 1.1 3 E9PWQ3 Collagen alpha-3 
(VI) chain 
9.5 ± 0.5 
4 Q922U2 Keratin, type II 
cytoskeletal 5 
4.0 ± 0.1 4 Q922U2 Keratin, type II 
cytoskeletal 5 
3.4 ± 0.4 4 Q60847 Collagen alpha-1 
(XII) chain 
3.5 ± 0.4 
5 Q60847 Collagen alpha-1 
(XII) chain 
3.6 ± 0.2 5 Q47739 Aldehyde  
dehydrogenase 
3.3 ± 0.1 5 Q922U2 Keratin, type II 
cytoskeletal 5 
3.4 ± 0.2 
6 Q47739 Aldehyde  
dehydrogenase 
3.5 ± 0.1 6 P40142 Transketolase 3.1 ± 0.1 6 Q47739 Aldehyde  
dehydrogenase 
3.1 ± 0.1 
7 P40142 Transketolase 3.5 ± 0.2 7 Q60847 Collagen alpha-1 
(XII) chain 
3.1 ± 0.4 7 Q02788 Collagen alpha-2 
(VI) chain 
3.0 ± 0.2 
8 Q64291 Keratin, type I 
cytoskeletal 12 
3.2 ± 0.1 8 Q02788 Collagen alpha-2 
(VI) chain 
2.9 ± 0.4 8 P40142 Transketolase 3.0 ± 0.3 
9 Q02788 Collagen alpha-2 
(VI) chain 
3.1 ± 0.1 9 Q64291 Keratin, type I 
cytoskeletal 12 
2.8 ± 0.4 9 Q04857 Collagen alpha-1 
(VI) chain 
2.9 ± 0.2 
10 Q04857 Collagen alpha-1 
(VI) chain 
2.9 ± 0.1 10 Q04857 Collagen alpha-1 
(VI) chain 
2.7 ± 0.3 10 Q64291 Keratin, type I 
cytoskeletal 12 
2.8 ± 0.2 
11 Q6GQT1 Alpha-2-macro- 
globulin-P 
1.8 ± 0.1 11 P24622 Alpha-crystallin A chain 2.1 ± 2.8 11 Q6GQT1 Alpha-2-macro- 
globulin-P 
1.6 ± 0.3 
12 O35367 Keratocan 1.7 ± 0.0 12 O35367 Keratocan 1.6 ± 0.2 12 O35367 Keratocan 1.6 ± 0.1 
113 P63260 Actin,  
cytoplasmic 2 
1.7 ± 0.1 13 Q6GQT1 Alpha-2-macro- 
globulin-P 
1.6 ± 0.1 13 P63260 Actin,  
cytoplasmic 2 
1.5 ± 0.1 
14 P07724 Serum albumin 1.5 ± 0.1 14 P63260 Actin,  
cytoplasmic 2 
1.6 ± 0.0 14 P07724 Serum albumin 1.3 ± 0.1 
15 Q8CGP2 Histone H2B 1.1 ± 0.0 15 P07724 Serum albumin 1.5 ± 0.2 15 Q8CGP2 Histone H2B 1.1 ± 0.1 
16 P82198 TGFBIp 1.0 ± 0.0 16 P23927 Alpha-crystallin B chain 1.1 ± 1.4 16 P51885 Lumican 0.9 ± 0.1 
17 O88207 Collagen alpha-1 
(V) chain 
1.0 ± 0.0 17 Q8CGP2 Histone H2B 1.0 ± 0.0 17 O88207 Collagen alpha-1 
(V) chain 
0.9 ± 0.2 
18 P51885 Lumican 0.9 ± 0.0 18 O88207 Collagen alpha-1 
(V) chain 
1.0 ± 0.2 18 P62806 Histone H4 0.8 ± 0.0 
19 P62806 Histone H4 0.9 ± 0.0 19 P51885 Lumican 0.9 ± 0.1 19 P02463 Collagen alpha-1 
(IV) chain 
0.8 ± 0.7 
20 P28654 Decorin 0.8 ± 0.0 20 P02463 Collagen alpha-1 
(IV) chain 
0.8 ± 0.8 20 P28654 Decorin 0.7 ± 0.1 
21 Q3U962 Collagen alpha-2 
(V) chain 
0.7 ± 0.0 21 P62806 Histone H4 0.8 ± 0.0 21 P82198 Collagen alpha-2 
(IV) chain 
0.7 ± 0.7 
22 Q62000 Mimecan 0.7 ± 0.0 22 P62696 Beta-crystallin B2 0.8 ± 1.0 22 P82198+ 
Q15582 
TGFBIp 0.7 ± 0.1 
23 Q61414 Keratin, type II 
cytoskeletal 15  
0.6 ± 0.1 23 P82198 Collagen alpha-2 
(IV) chain 
0.8 ± 0.7 23 Q3U962 Collagen alpha-2 
(V) chain 
0.6 ± 0.1 
24 O09131 Glutathione  
S-transferase 
0.6 ± 0.0 24 P82198 + 
Q15582 
TGFBIp 0.7 ± 0.1 24 Q61414 Keratin, type II 
cytoskeletal 15  
0.6 ± 0.2 
25 P84228 Histone H3.2 0.5 ± 0.0 25 Q3U962 Collagen alpha-2 
(V) chain 
0.7 ± 0.1 25 Q62000 Mimecan 0.6 ± 0.1 
The molar percentage was calculated by dividing the LFQ intensity for a given protein by the total LFQ intensity for all proteins in a given 
sample. Proteins were included if quantified in all three biological replicates in one group. 
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